Psilocybin for Eating Disorders

Psilocybin for Eating Disorders: Emerging Research

Anorexia nervosa has the highest mortality rate of any psychiatric disorder — approximately 10% of people diagnosed with anorexia die from its complications within 10 years. It is also among the most treatment-resistant conditions in psychiatry: existing treatments produce full recovery in fewer than half of patients, and relapse is common. This combination — severe mortality risk and limited treatment options — has made eating disorder researchers willing to investigate treatments far outside the conventional pharmacological toolkit.

Psilocybin is one of them. The early evidence is preliminary but credible, and the mechanistic case is compelling.

The Clinical Evidence

Imperial College London — Anorexia Nervosa Pilot (2023)

The landmark early study. Cynthia Bir and Dasha Nicholls at Imperial College London conducted an open-label pilot of psilocybin-assisted therapy in 10 adults with anorexia nervosa — the first such trial anywhere.

Key results at 1-month follow-up:

• Significant reductions in eating disorder psychopathology (measured by EDE-Q)
• Reductions in BMI-related preoccupation (a key driver of anorexia behavior)
• No serious adverse events
• Several participants described the experience as allowing them to see their relationship with food and body from outside the disorder for the first time

This was n=10, open-label, no control group. It establishes that psilocybin can be administered safely in this population (a major concern given anorexia's medical complications) and that it may produce meaningful symptom changes. It does not establish efficacy.

University of California San Diego (UCSD) — Psilocybin for Anorexia (2024–ongoing)

Following Imperial's pilot, UCSD launched the first North American randomized controlled trial of psilocybin for anorexia nervosa. The trial compares psilocybin (25mg) to low-dose active control (1mg psilocybin) with specialized eating disorder psychotherapy.

Status as of 2026: Recruiting and early phase. Results expected 2027–2028.

Johns Hopkins — Anorexia Investigation

Johns Hopkins has announced a psilocybin anorexia protocol building on their depression and addiction research. Status: protocol development and early recruitment.

Bulimia Nervosa and Binge Eating Disorder

No major trials as of 2026, though several researchers have argued that the mechanistic case for psilocybin in binge eating disorder (which involves impulsivity, compulsivity, and self-regulatory failure similar to addiction) is as strong as for anorexia. Preliminary case reports suggest potential. First trials expected 2026–2028.

Why Psilocybin? The Mechanism

Anorexia nervosa is not simply a disorder of eating behavior. It involves:

• Profoundly rigid and distorted body image
• Deeply embedded self-narrative (often identity-level: "I am someone who controls what I eat")
• Compulsive thinking and ritual behavior (analogous to OCD)
• Hyperactivity in the default mode network — the self-referential processing system that drives rumination

Psilocybin addresses several of these simultaneously:

Default mode network disruption. Psilocybin reliably reduces DMN activity, interrupting the self-referential loops that maintain distorted body image and eating disorder cognitions.

Ego dissolution and body perception. High-dose psilocybin often produces experiences where ordinary boundaries of self dissolve. For anorexia patients, this frequently includes encounters with the body that bypass the distorted self-perception of the disorder — participants have described "seeing their body as it actually is" in ways their ordinary perception does not allow.

Neuroplasticity window. Post-psilocybin neuroplasticity elevation creates a period in which eating disorder-related thought patterns and behaviors may be more amenable to change through specialized therapy.

The mystical experience correlation. As in depression and addiction, mystical-type experience ratings correlate with treatment outcome in eating disorder pilots. The experience of profound meaning and connection appears to directly address the disconnection and meaninglessness that drive anorexia's "why eat at all?" question.

Medical Considerations: Special Risks in Eating Disorders

Eating disorders involve specific medical complications that require careful management before and during psilocybin treatment. These are not reasons to exclude the population — they are reasons for specialized medical monitoring:

Cardiac risk: Anorexia causes cardiac muscle wasting and electrolyte abnormalities (hypokalemia, hyponatremia) that increase arrhythmia risk. Psilocybin elevates heart rate and blood pressure at peak. Any anorexia patient pursuing psilocybin must have cardiac evaluation, electrolyte normalization, and ECG baseline before treatment.

Hypoglycemia: Anorexia patients may be hypoglycemic, particularly during fasting periods. Medical monitoring during the session is important.

Medication interactions: Many anorexia patients are on SSRIs (which blunt psilocybin effects) or atypical antipsychotics (olanzapine is commonly used for weight gain in anorexia — its 5-HT2A blocking activity may partially antagonize psilocybin).

Minimum weight threshold: Clinical trials generally require participants to be at a minimum BMI (often 16–17+) and medically stable. Severely underweight patients face increased risk during high-intensity psilocybin experiences and require medical stabilization first.

The Therapy Component

Psilocybin for eating disorders is not being investigated as a standalone pharmacological treatment — it is being studied as a catalyst for specialized eating disorder therapy. The therapeutic container matters enormously.

Eating disorder-specific concerns in the psilocybin therapy framework:

Body scan exercises in preparation: Many mindfulness-based body awareness practices are contraindicated in eating disorders (they can trigger disorder-related preoccupation). Preparation sessions require eating disorder-specific adaptation.

Identity disruption: For patients whose identity is deeply organized around the eating disorder, the ego dissolution that can occur at high psilocybin doses may be destabilizing without appropriate preparation and support. Therapists need both psychedelic facilitation training and eating disorder clinical competence.

Integration focus: Post-session therapy should work specifically with what arose about body image, self-perception, and the patient's relationship with the disorder — not just generic integration support.

Who Is Pursuing This Treatment

The population most likely to access psilocybin eating disorder treatment at this stage:

• Adults (18+) with anorexia nervosa, at stable medical weight, who have engaged in conventional treatment (CBT, FBT, DBT, inpatient) without adequate recovery
• Individuals who are willing to participate in clinical trials, which offer free treatment with the highest safety monitoring
• People seeking service center treatment in Oregon or Colorado with eating disorder-specific preparation and integration support (exists but limited as of 2026)

Not appropriate for:

• Active severe underweight (BMI < 16 without medical supervision)
• Unstable cardiac status or active electrolyte abnormalities
• Active purging that creates electrolyte risk
• Minors (trials have not yet enrolled under-18 participants)

Access in 2026

Clinical Trials

The only currently available structured treatment context with appropriate medical monitoring. Check ClinicalTrials.gov: "psilocybin anorexia" or "psilocybin eating disorder."

Active as of 2026:

• UCSD: Randomized controlled trial, anorexia nervosa
• Johns Hopkins: Pilot protocol in development
• International: Several European sites following the Imperial College work

Treatment in trials is free. Trials include medical monitoring that is essential in this population.

Oregon and Colorado Service Centers

Legally available for adults. Requires careful vetting of the service center's ability to work with eating disorder populations — most facilitators do not have specialized eating disorder training. Ask directly:

• Do you have experience with eating disorder clients?
• How do you adapt preparation work for body image concerns?
• What is your medical monitoring capacity during sessions?
• What integration resources do you have or can you refer to?

If these questions don't produce credible answers, this is not the right setting.

Honest Assessment

Psilocybin for eating disorders is at the earliest credible stage: a plausible mechanism, initial safety data, and one published pilot suggesting symptom reduction. The field is moving quickly because the unmet need is enormous — anorexia kills at a rate that justifies investigating treatments with limited evidence. But "limited evidence" is important to name honestly.

For someone with severe, treatment-resistant anorexia who has engaged in conventional treatment, clinical trial participation is worth pursuing. This is a population where the risk-benefit calculation favors investigation rather than waiting for more data.

For someone earlier in their treatment course, conventional evidence-based treatments (CBT-E, FBT, inpatient weight restoration) should come first. Psilocybin is not a first-line intervention and has not been studied in treatment-naive eating disorder populations.

Resources

• ClinicalTrials.gov — Search "psilocybin anorexia" for enrolling trials
• National Eating Disorders Association (NEDA) — nationaleatingdisorders.org — helpline: 1-800-931-2237
• Project Heal — theprojectheal.org — treatment access support for eating disorders
• Fireside Project — 623-473-7433 — support during/after psilocybin experiences
• Alliance for Eating Disorders Awareness — allianceforeatingdisorders.com — provider directory